Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-04-30

Development of a dna vector for the treatment of haemophilia a using gene therapy technologies

Objectif



Current treatment regimes for Haemophilia A involve the frequent administration of plasma derived or recombinant human Factor VIII (hFVIII). However, treatment is restricted by the availability, short half-life and high cost of purifled hFVIII. Therefore, we propose to develop a clinical gene therapy protocol suitable for the treatment of patients suffering from Haemophilia A.
To achieve this we propose to assess a number of eukaryotic promoters for cell type specificity in addition to persistence of on in lineages derived from hematopoietic stem cells. These promoters will then be transferred into a retroviral backbone where they will regulate expression of the hFVIII cDNA. Hematopoietic cells will be obtained from patients bone marrow, transduced in vitro, prior to reimplantation into the patients. Peripheral blood cells derived from the transduced hematopoietic stem cells are expected to secrete hFvIII directly into the plasma resulting in the systemic correction of the condition.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Appel à propositions

Données non disponibles

Régime de financement

RGI - Research grants (individual fellowships)

Coordinateur

KAROLINSKA INSTITUTE
Contribution de l’UE
Aucune donnée
Adresse
Haelsvaegen 7
141 57 Huddinge
Suède
Coût total
Aucune donnée

Participants (1)